Nateglinide
CAS No. 105816-04-4
Nateglinide ( A-4166; SDZ-DJN 608 )
产品货号. M10264 CAS No. 105816-04-4
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
纯度: >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥332 | 有现货 |
|
25MG | ¥672 | 有现货 |
|
50MG | ¥1199 | 有现货 |
|
100MG | ¥2017 | 有现货 |
|
200MG | ¥2908 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Nateglinide
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
-
产品描述Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
-
同义词A-4166; SDZ-DJN 608
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体Potassium Channel; PPARγ
-
研究领域Cardiovascular Disease
-
适应症——
化学信息
-
CAS Number105816-04-4
-
分子量317.42
-
分子式C19H27NO3
-
纯度>98%(HPLC)
-
溶解度Ethanol: 63 mg/mL (198.47 mM); DMSO: 63 mg/mL (198.47 mM)
-
SMILESO=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
-
化学全称(R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52.
产品手册
关联产品
-
VU591 hydrochloride
VU591 hydrochloride is a selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50:0.24 μM).?Thought to block the intracellular pore of the Kir1.1 channel.?Exhibits no effect on Kir7.1 at concentrations up to 10 μM;?does not inhibit Kir2.1, Kir2.3 or Kir4.1.?
-
AVE-0118
AVE-0118 is a potent I(to)/I(Kur) blocker, Kv1.5 channel inhibitor with IC50 of 5.6 uM.
-
Almitrine dimesylate
Almitrine dimesylate inhibits selectively the Ca2+-dependent K+ channel and that in rat chemoreceptor cellsused in the treatment of hypoxemic chronic lung diseases.